ClinicalTrials.gg
CompletedNCT04812860Updated Jun 22, 2025

A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth.

A Phase 2 interventional study of HR18042 and HR18042 in Moderate to Severe Acute Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2020, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Acute Pain with a site in China — 8 open to participants now, 9 under way, none of them phase 3. Acute Pain · China.

Enrollment
8th of 18
187 · median 152
Started
2020
the only one that year
Phase 2
2 of 23
none open now
Registered
7th of 23
by date
Lead sponsor
1 of 23
Jiangsu HengRui Medicine Co., Ltd.

Among the 23 studies in Acute Pain with a site in China, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2, and was the 7th registered.

Acute Pain

1,076 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

8 of the 23 studies in Acute Pain with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Acute Pain with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the Efficacy and safety of HR18042 tablets for the Treatment of Post-surgical Pain After extraction of impacted tooth, find the optimal dose.

03

Conditions studied

  • Moderate to Severe Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old.
  2. Subjects must have a plan of extraction of impacted tooth.
  3. Subjects with moderate to severe pain (VAS score ≥ 50mm).This must be measured within a maximum of 4 hours after the end of extraction of impacted tooth.
  4. weight at least 45kg,and no more than 100kg.
  5. If a female is of , she must be using highly effective methods of throughout the study.
  6. Willingness to comply with the study procedures and requirements.
  7. willing and able to provide written for this study.

Exclusion criteria

Exclusion Criteria:

  1. any analgesic medication other than preoperative or intraoperative anaesthetic agents within 12h before taking trial medication medication
  2. a longacting NSAID within 4 days,or a shortacting NSAID within 1 days prior to dosing.
  3. any anti-depressive medication, selective serotonin reuptake inhibitors (SSRIs), diet pills et.al. with 30 days of study entry.
  4. Oral surgical site combined with infection.
  5. Severe cardiovascular and cerebrovascular diseases.
  6. Severe gastrointestinal disease.
  7. had a history of seizures or drug or alcohol abuse.
  8. uncontrolled hypertension.
  9. significant abnormal
  10. significant abnormal laboratory value.
  11. Allergic to the study drug and ingredients.
  12. Pregnancy, lactation or recent Pregnant plan;
  13. Subjects who participated in a clinical research study involving an experimental drug before 30 days of study entry.
  14. other conditions unsuitable for participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    HR18042 100mg

    Drug: HR18042

  • Experimental
    HR18042 125mg

    Drug: HR18042

  • Experimental
    HR18042 200mg

    Drug: HR18042

  • Active comparator
    Tramadol hydrochloride ER 100mg

    Drug: Tramadol hydrochloride ER

  • Placebo comparator
    Placebo to match HR18042 and Tramadol hydrochloride ER

    Drug: Placebo

Interventions

  • DrugHR18042

    Tablet, Dosing frequency: once daily, Route of administration: oral

  • DrugHR18042

    Tablet,Dosing frequency: once daily, Route of administration: oral

  • DrugHR18042

    Tablet,Dosing frequency: once daily, Route of administration: oral

  • Tablet,Dosing frequency: once daily, Route of administration: oral

  • DrugPlacebo

    Tablet,Dosing frequency: once daily, Route of administration: oral

06

What researchers measure

Primary outcomes

  1. the Sum of Pain Intensity Differences(SPID)

    SPID is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.

    Time frame: 0-8hours

Secondary outcomes

  1. the Sum of Pain Intensity Differences(SPID)

    Time frame: 0-4hours

  2. the Sum of Pain Intensity Differences(SPID)

    Time frame: 0-12hours

  3. Pain Intensity Differences(PID)

    Include pain intensity differences(PIDs) from baseline at each time point. measured at different time points via the PI-VAS.

    Time frame: 0-12hours

  4. Pain relief(PAR)

    pain relief (PAR) on a 5-point Likert scale (0, none, 1, a little, 2, some,3, a lot, 4, complete).

    Time frame: 0-12hours

  5. the Sum of Pain relief Differences(SPAR)

    SPAR is derived as the weighted Sum of Pain relief, measured at different time points via the 5-point Likert scale. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.

    Time frame: 0-4hours

  6. the Sum of Pain relief Differences(SPAR)

    Time frame: 0-8hours

  7. the Sum of Pain relief Differences(SPAR).

    Time frame: 0-12hours

  8. Subject who reaches a 30% reduction in pain intensity from baseline

    Time frame: 4hours、8hours、12hours

  9. Subject who reaches a 50% reduction in pain intensity from baseline

    Time frame: 4hours、8hours、12hours

  10. time to perceptible pain relief

    Time frame: 0-12hours

  11. time to meaningful pain relief

    Patients used one stopwatch to record the time to 'perceptible' PAR and another stopwatch for the time to'meaningful' PAR.Patients started timing upon intake of study medication and stopped one stopwatch at the onset of perceptible PAR and another upon achieving meaningful PAR.

    Time frame: 0-12hours

  12. Time to first use of rescue medication

    Time frame: 0-12hours

  13. Proportion of subjects who take of at least 1 dose of rescue medication

    Time frame: 0-12hours

  14. Subject's overall assessment of study medication

    Patients made an overall assessment of the study medication using a verbal rating scale (excellent, verygood, good, fair, poor).

    Time frame: 12hours

07

Study locations

1 site
  • West China Hospital of Stomatology Sichuan University
    Chengdu, Sichuan 610041, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2021, 1 month.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Mar 24, 2021
StartActual
Dec 8, 2020
Primary completionActual
Jan 25, 2021
CompletionActual
Jan 25, 2021
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04812860
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Dec 8, 2020
Primary completion
Jan 25, 2021
Completion
Jan 25, 2021
Last update
Jun 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion